KURA Reports Positive Phase 1 FIT-001 For Darlifarnib-Adagrasib In KRASG12C-Mutated Solid Tumors

Kura Oncology reported positive phase 1 results for darlifarnib, its next-generation farnesyl transferase inhibitor, in combination with adagrasib. The update is encouraging for the company’s oncology pipeline and supports the underlying development thesis, though it is still early-stage clinical data. The news is likely to be positive for the stock, but the market impact should remain limited until more mature trial results are released.

Analysis

Kura Oncology reported positive phase 1 results for darlifarnib, its next-generation farnesyl transferase inhibitor, in combination with adagrasib. The update is encouraging for the company’s oncology pipeline and supports the underlying development thesis, though it is still early-stage clinical data. The news is likely to be positive for the stock, but the market impact should remain limited until more mature trial results are released.